tiprankstipranks
Trending News
More News >

AstraZeneca doses first patient in DESTINY-Endometrial01 trial

The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating Enhertu in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer. DESTINY-Endometrial01 will be conducted in collaboration with The GOG Foundation, Inc. and the European Network of Gynecological Oncological Trial.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue